Wegovy (semaglutide) and Adderall (mixed amphetamine salts) are two distinct prescription medications serving fundamentally different therapeutic purposes, though patients may occasionally require both for separate medical conditions
Factors influencing success rate: Search Engine Optimization (SEO): How well the website ranks in search engine results
Compounded GLP-1s are not FDA-approved products
12.31.23 Nearly 6,500 adverse events connected to GLP-1 medications reported in 2023 6,487 total cases, including 89 deaths
The efficacy of Wegovy on liver histology was assessed in a Week 72 analysis using post-baseline biopsies from the first 800 patients (with F2 or F3 at eligibility), who were randomized 1:2 to receive placebo (n=266) or Wegovy once weekly (n=534), in addition to standard of care for cardiometabolic comorbidities and healthy lifestyle counseling.* Wegovy or matching placebo was escalated to 2.4 mg once weekly during the initial 16 weeks of the treatment period
Reported patronage of fast-food, casual, and upscale restaurants all declined among GLP-1 users in March/April from the previous reporting period in Feb/March
